RANI — Rani Therapeutics Holdings Share Price
Last trade - 00:00- $73.40m
- $35.49m
- $1.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.16 | ||
| Price to Tang. Book | 2.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.98% | ||
| Return on Equity | -248.6% | ||
| Operating Margin | -539.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.72 | n/a | n/a | 1.03 | 1.63 | 6.71 | 5.65 | 28.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Directors
- Jean-Luc Butel IND (69)
- Dennis Ausiello IND (80)
- Mir Imran CHM (68)
- Mir Hashim CSO (66)
- Talat Imran CEO (44)
- Eric Groen GCN (55)
- Kate McKinley OTH (48)
- Abraham Bassan DRC (41)
- Vasudev Bailey DRC (41)
- Alireza Javadi CTO
- Nicholas Maestas CFO (46)
- Michelle Gilson DRC (34)
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- April 6th, 2021
- Public Since
- July 30th, 2021
- No. of Shareholders
- 115
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 139,460,921
- Address
- 2051 Ringwood Avenue, SAN JOSE, 95131
- Web
- https://www.ranitherapeutics.com
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Latest News for RANI
Upcoming Events for RANI
Similar to RANI
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 12:53 UTC, shares in Rani Therapeutics Holdings are trading at $0.53. This share price information is delayed by 15 minutes.
Shares in Rani Therapeutics Holdings last closed at $0.53 and the price had moved by -72.73% over the past 365 days. In terms of relative price strength the Rani Therapeutics Holdings share price has underperformed the S&P500 Index by -75.71% over the past year.
The overall consensus recommendation for Rani Therapeutics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRani Therapeutics Holdings does not currently pay a dividend.
Rani Therapeutics Holdings does not currently pay a dividend.
Rani Therapeutics Holdings does not currently pay a dividend.
To buy shares in Rani Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.53, shares in Rani Therapeutics Holdings had a market capitalisation of $73.40m.
Here are the trading details for Rani Therapeutics Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RANI
Based on an overall assessment of its quality, value and momentum Rani Therapeutics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rani Therapeutics Holdings is $6.25. That is 1087.54% above the last closing price of $0.53.
Analysts covering Rani Therapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.17 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rani Therapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -52.29%.
As of the last closing price of $0.53, shares in Rani Therapeutics Holdings were trading -41.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rani Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rani Therapeutics Holdings' management team is headed by:
- Jean-Luc Butel - IND
- Dennis Ausiello - IND
- Mir Imran - CHM
- Mir Hashim - CSO
- Talat Imran - CEO
- Eric Groen - GCN
- Kate McKinley - OTH
- Abraham Bassan - DRC
- Vasudev Bailey - DRC
- Alireza Javadi - CTO
- Nicholas Maestas - CFO
- Michelle Gilson - DRC